{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T13:10:17Z","timestamp":1759151417486,"version":"3.44.0"},"reference-count":29,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1136\/dtb.2025.000009","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T15:20:13Z","timestamp":1758295213000},"page":"150-155","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Mavacamten (\u25bcCamzyos) for obstructive hypertrophic cardiomyopathy"],"prefix":"10.1136","volume":"63","clinical-trial-number":[{"clinical-trial-number":"nct03470545","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04349072","registry":"10.18810\/clinical-trials-gov"}],"member":"239","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"2025092905451589000_63.10.150.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad194"},{"key":"2025092905451589000_63.10.150.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31321-6"},{"key":"2025092905451589000_63.10.150.3","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1016\/S0140-6736(21)01205-8","article-title":"Hypertrophic cardiomyopathy: a practical approach to guideline directed management","volume":"398","author":"Ommen","year":"2021","journal-title":"The Lancet"},{"key":"2025092905451589000_63.10.150.4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-077274","article-title":"Current management of hypertrophic cardiomyopathy","volume":"389","author":"Sikand","year":"2025","journal-title":"BMJ"},{"key":"2025092905451589000_63.10.150.5","unstructured":"Center for Drug Evaluation and Research . Application number 214998orig1s000 cinical and statistical review(s) [online]. 2022. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/214998Orig1s000Med_StatR.pdf [Accessed 4 Sep 2025]."},{"key":"2025092905451589000_63.10.150.6","unstructured":"National Institute for Health and Care Excellence . Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913) [online]. 2023. Available: www.nice.org.uk\/guidance\/ta913 [Accessed 4 Sep 2025]."},{"key":"2025092905451589000_63.10.150.7","unstructured":"Camzyos 2.5 mg hard capsules. Summary of Product Characteristics, GB. Bristol-Myers Squibb Pharma EEIG ; June 2025."},{"key":"2025092905451589000_63.10.150.8","unstructured":"European Medicines Agency . Assessment report: Camzyos [online]. 2023. Available: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/camzyos-epar-public-assessment-report_en.pdf [Accessed 4 Sep 2025]."},{"key":"2025092905451589000_63.10.150.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31792-X"},{"key":"2025092905451589000_63.10.150.10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cardfail.2024.08.061","article-title":"The Kansas City Cardiomyopathy Questionnaire in Relation to New York Heart Association Class","volume":"31","author":"Sherrod","year":"2025","journal-title":"J Card Fail"},{"key":"2025092905451589000_63.10.150.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.09.1381"},{"key":"2025092905451589000_63.10.150.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.04.048"},{"key":"2025092905451589000_63.10.150.13","unstructured":"Desai MY , Owens A , Gesken JB . Supplement 3: online content. 2022. Available: https:\/\/www.jacc.org\/doi\/suppl\/10.1016\/j.jacc.2022.04.048\/suppl_file\/mmc1.docx [Accessed 4 Sep 2025]."},{"key":"2025092905451589000_63.10.150.14","doi-asserted-by":"crossref","first-page":"6097","DOI":"10.1097\/MS9.0000000000002466","article-title":"Efficacy and safety of mavacamten for the treatment of hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of randomized controlled trials","volume":"86","author":"Almansouri","year":"2024","journal-title":"Annals of Medicine & Surgery"},{"key":"2025092905451589000_63.10.150.15","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","article-title":"Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial","volume":"8","author":"Tian","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2025092905451589000_63.10.150.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(20)33276-9"},{"key":"2025092905451589000_63.10.150.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00531-3"},{"key":"2025092905451589000_63.10.150.18","unstructured":"Bristol Myers Squibb . Risk materials [online]. 2025. Available: https:\/\/www.medicines.org.uk\/emc\/product\/15030\/rmms [Accessed 4 Sep 2025]."},{"key":"2025092905451589000_63.10.150.19","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1093\/eurheartj\/ehad429","article-title":"The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients","volume":"44","author":"DeVries","year":"2023","journal-title":"Eur Heart J"},{"key":"2025092905451589000_63.10.150.20","unstructured":"Medicines and Healthcare products Regulatory Agency . Public assessment report national procedure [online]. 2024. Available: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/16c463c53f3ee48479bc36f92f021f3a813a1898 [Accessed 4 Sep 2025]."},{"key":"2025092905451589000_63.10.150.21","unstructured":"Therapeutics Goods Administration . Australian Public Assessment Report for Camzyos [online], 2023. Available: https:\/\/www.tga.gov.au\/sites\/default\/files\/2023-07\/auspar-camzyos-230703.pdf [Accessed 4 Sep 2025]."},{"key":"2025092905451589000_63.10.150.22","unstructured":"NHS England . Cardiology: inherited cardiac conditions (all ages) [online]. 2017. Available: https:\/\/www.england.nhs.uk\/publication\/cardiology-inherited-cardiac-conditions-all-ages\/ [Accessed 4 Sep 2025]."},{"key":"2025092905451589000_63.10.150.23","unstructured":"Joint Formulary Committee . British National Formulary [online]. 2025. Available: https:\/\/bnf.nice.org.uk\/ [Accessed 4 Sep 2025]."},{"key":"2025092905451589000_63.10.150.24","unstructured":"Scottish Medicines Consortium . Mavacamten (Camzyos) [online]. 2024. Available: https:\/\/scottishmedicines.org.uk\/medicines-advice\/mavacamten-camzyos-full-smc2618\/ [Accessed 4 Sep 2025]."},{"key":"2025092905451589000_63.10.150.25","unstructured":"Canadian Agency for Drugs and Technologies in Health . CADTH reimbursement review: mavacamten (Camzyos) [online]. 2023. Available: https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2023\/SR0755-Camzyos.pdf [Accessed 4 Sep 2025]."},{"key":"2025092905451589000_63.10.150.26","first-page":"33","article-title":"Mavacamten (Camzyos) in hypertrophic cardiomyopathy","volume":"34","year":"2025","journal-title":"Prescrire Int"},{"key":"2025092905451589000_63.10.150.27","first-page":"89","article-title":"Mavacamten (Camzyos) for obstructive hypertrophic cardiomyopathy","volume":"64","year":"2022","journal-title":"Med Lett Drugs Ther"},{"key":"2025092905451589000_63.10.150.28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.18773\/austprescr.2025.006","article-title":"New Drug: Mavacamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"48","year":"2025","journal-title":"Aust Prescr"},{"key":"2025092905451589000_63.10.150.29","unstructured":"National Institute of Health and Care Excellence . Clinical Knowledge Summaries: heart failure \u2013 chronic [online]. 2025. Available: https:\/\/cks.nice.org.uk\/topics\/heart-failure-chronic\/ [Accessed 4 Sep 2025]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2025.000009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T12:45:34Z","timestamp":1759149934000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2025.000009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,9,29]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/dtb.2025.000009"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2025.000009","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2025,9,19]]}}}